In vitro study demonstrates tunable light-activated butyrylcholinesterase inhibition using carbon quantum dot hybrids, indicating high promise for customizable photopharmacology.
Light-responsive materials enabling external modulation of bioactivity and spatial control are highly requested for photopharmacology—a booming research area of modern medicine. We present organo-inorganic hybrids of photoswitchable, bioactive symmetric diamine-phosphine oxides conjugated with luminescent carbon quantum dots (CQDs). The phosphonate compound was found to undergo Z-E isomerization upon 266 nm laser irradiation and exhibit butyrylcholinesterase (BChE) inhibition that increases twofold (15–30%) after photoconversion. Hybrids were fabricated via physical adsorption and chemisorption using different CQD surface groups, and characterized by UV-Vis, luminescence, and FTIR spectroscopy, confirming hybrid formation and retention of functional properties. In both binding modes, the molecules retained photoswitching capability despite steric constraints. All hybrids displayed orthogonal functions: luminescence (excitation at 350 nm) and photomodulation of BChE inhibition (at 266 nm). Remarkably, the binding mode dictated the bioactivity window—chemisorbed hybrids showed narrow 1.5-fold modulation, whereas physisorbed hybrids exhibited ultra-wide >10-fold modulation. This tunable responsiveness, achieved simply by altering the binding mode, demonstrates the exceptional potential of this hybrid design strategy for developing photoswitchable materials with tailored photopharmacological performance.
No takes yet. Share an insight, caveat, or question.
Kolesnikov et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: